Results 211 to 219 of about 39,316 (219)

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Lancet, The, 2019
Phillipe Moreau, Michel M Attal, `Cyrille Hulin   +2 more
exaly  

Success in translational research: lessons from the development of bortezomib

Nature Reviews Drug Discovery, 2006
exaly  

A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance

Cancer Cell, 2012
Bin Zhou, Mikael Altun, Benedikt M. Kessler   +2 more
exaly  

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

New England Journal of Medicine, 2017
Michel M Attal, Xavier Leleu, Karim Belhadj   +2 more
exaly  

Restoration of chemosensitivity by bortezomib: implications for refractory myeloma

Nature Reviews Clinical Oncology, 2009
Cs Chim
exaly  

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

Lancet Oncology, The, 2010
María-Victoria Mateos, Albert Oriol, Joaquin Martinez-Lopez   +2 more
exaly  

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

New England Journal of Medicine
Tobias Silzle
exaly  

Bortezomib

Reactions Weekly, 2019
openaire   +1 more source

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

New England Journal of Medicine
exaly